Trends in Health Technology Assessment

Date: May 22, 2011
Pages: 120
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T2394D61AA6EN

Download PDF Leaflet

Trends in Health Technology Assessment
Global License: US$ 14,780.00


The report explores approaches to HTA, profiles HTA organizations in six countries (Australia, Canada, France, Germany, the UK, and the US) and examines how their results are used to inform pricing and reimbursement decisions. The focus is on pharmaceuticals, medical devices, and diagnostics and how the rapidly evolving HTA environment will influence future market access of these technologies.

Features and benefits
  • Analyze what evidence is required for HTA evaluations to show that a particular drug/medtech product represents an improvement on current practice.
  • Gain an insight into HTA programs & identify common trends in assessment practices and areas where there are differences in processes and procedures.
  • Evaluate how P&R policies are influenced by HTA outcomes and what impact HTA advice has on payors and providers, supported by case studies.
  • Assess industry’s role in providing evidence that meets diverse HTA demands.
  • Evaluate how interaction between regulators and payors could pave the way for greater synergies between regulatory and HTA requirements.

Clinical and cost effectiveness are assessed for pharmaceuticals in Australia, Canada and the UK, while clinical benefit is the main focus in France and Germany for new drugs. CER is rapidly gaining momentum in the US to inform federal funding decisions, while commercial US payors use clinical and economic evidence in formulary listings.

Patient input is gaining greater significance in HTA, helping to provide a broader perspective of a product’s value in the real world setting. By February 2011, 22 drugs had benefited from the new process for patient group input during the Canadian Common Drug Review since it was introduced in May 2010.

From January 2011, the clinical benefit of all new pharmaceuticals launched in Germany must be assessed on the basis on manufacturers’ dossiers. The introduction of value-based pricing in the UK in 2014 will require all new brand medicines to demonstrate value, replacing the current system of selective appraisals by NICE.

Your key questions answered
  • What factors are used by different HTA bodies to measure the costs and benefits of health technologies?
  • How is advice provided by HTA organizations used by different payors?
  • How can companies best approach the need to incorporate HTA requirements into their product development plans?
  • What are the key challenges of HTA and what efforts are underway to address theses?
  • Which organizations are involved in HTA in Australia, Canada, France, Germany, the UK, and the US?
Executive Summary
  Overview of health technology assessment
  National HTA organizations profiled
  HTA in practice
  Influence of HTA on pricing and reimbursement
  Industry’s role in HTA
  Future perspectives
About the author
Overview of health technology assessment
  Definition of HTA
    HTA processes
  Evolution of HTA
  Collaborative initiatives
  Key HTA principles
  Influence of HTA on pharma/medtech
National HTA organizations profiled
    Provincial HTA organizations
    Pharmaceutical HTA
    Medical device HTA
    NICE technology appraisals
    Evaluation Pathway Program
    Private sector
HTA in practice
  Stakeholder involvement
    Patient input
    Canada’s new process for CDR
  Calculating cost-effectiveness
    NICE threshold
    Theoretical thresholds
    Cost minimization
    Efficiency frontier
    Cost-consequence analysis
  Timeliness of HTA
Influence of HTA on pricing and reimbursement
  Uptake of HTA advice by payors
    Australian government overrides PBAC advice
    Listing of drugs assessed centrally in Canada
  Dual recommendations in France
    Medical devices
  Germany’s new early assessment procedure
    HTA of older products
  Implementation of advice by providers
    Future role of NICE
  Changing US landscape
    CMS coverage of Provenge
  Tackling uncertainty
    US CED
    Ontario’s cancer drug scheme
    UK patient access schemes
    Managed entry in Australia
Industry’s role in HTA
  European Tapestry Network
    Swiss HTA consensus
  Industry case study
  Industry relationship with payors/policy-makers
  Regulator/HTA/payor interaction
    UK pilot parallel scientific advice process
    Sweden’s experience with parallel advice
    US collaboration
Future perspectives
  Increased scope of HTA
    Orphan drugs
  HTA as part of product development
  HTA and market access schemes
  Convergence of HTA programs
    EU HTA co-operation
  Relative effectiveness/comparative effectiveness
  Summary of conclusions
    Secondary research
Skip to top

Ask Your Question

Trends in Health Technology Assessment
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: